摘要
为了观察伊立替康联合顺铂治疗广泛期小细胞肺癌(SCLC)的近期疗效及毒副反应,对28例患者采用伊立替康联合顺铂治疗的方法。伊立替康60mg/m2,静脉滴入,d1、d8、d15;顺铂60mg/m2,静脉滴入,d1。28d为1个周期,2个周期后评价疗效。结果可评价疗效28例,其中CR6例(21.4%),PR12例(42.9%),NC4例(14.3%),PD6例(21.4%),总有效率为64.3%(18/28)。主要毒副反应为腹泻、骨髓抑制、恶心和呕吐。初步结果提示,伊立替康联合顺铂治疗SCLC有明显的疗效,毒副反应可以耐受,可以作为SCLC临床治疗的有效方案之一。
The objective of this study was to evaluate the efficacy and side effects of irinotecan plus cisplatin in the treatment of patients with extensive-stage small cell lung cancer（SCLC）.Twenty-eight patients with extensive-stage small cell lung cancer were treated with irinotecan plus cisplatin.Irinotecan was given at a dose of 60 mg/m2,d1,d8,d15;cisplatin 60 mg/m2,d1.This regimen was repeated every 28 days.Affter two cycles the effect was evaluated All the cases could be evaluated.There were CR 6（21.4%）,PR 12（42.9%）,NC 4（14.3%）,PD 6（21.4%）,the overall response rate was 64.3%（18/28）.The main toxicity and side effects were diarrhea,myelosuppression,nausea and vomit.In conclusion,irinotecan plus cisplatin is an effective and tolerable regimen in the treatment of extensive-stage small-cell lung cancer.
出处
《中华肿瘤防治杂志》
CAS
2009年第20期1612-1613,共2页
Chinese Journal of Cancer Prevention and Treatment
关键词
肺肿瘤/药物疗法
药物疗法
联合
癌
非小细胞肺
lung neoplasms/drug therapy
drug therapy
combiration
careinoma
small cell
作者简介
【通讯作者简介】韩娜，女，河南唐河人，硕士，主治医师，主要从事晚期肿瘤综合治疗的研究工作。Tel：86—371—63974597 E—mail：hannana2005@yahoo．cn
